St. Luke's Episcopal Hospital

Summary

St. Luke's Episcopal Hospital is a medical facility located in Houston, Texas. This center is recognized for care of Coronary Artery Disease, Hepatitis C, Atrial Fibrillation, Heart Failure, Pancreatic Cancer and other specialties. St. Luke's Episcopal Hospital is involved with conducting 147 clinical trials across 233 conditions. There are 22 research doctors associated with this hospital, such as Mohamed O. Othman, MD, Joseph Coselli, MD, Guilherme Silva, MD, and Benjamin Musher.

Top PIs

Clinical Trials running at St. Luke's Episcopal Hospital

Heart Failure

Brain Tumor

Breast Cancer

Pancreatic Cancer

Heart Disease

Cardiovascular Disease

Pulmonary Hypertension

Chronic Myeloid Leukemia

Glioblastoma

Brain Cancer

Omecamtiv Mecarbil

for Heart Failure

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

Recruiting

1 award

Phase 3

10 criteria

Mechanical Circulatory Support

for Heart Failure

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

Recruiting

1 award

N/A

3 criteria

Mavacamten

for Hypertrophic Cardiomyopathy

This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment. United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting. Europe Sub-Study: The purpose of this study is to evaluate the effectiveness and safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.

Recruiting

1 award

N/A

10 criteria